8-K current report · filed Sep 15, 2026

ROCKET PHARMACEUTICALS, INC. (RCKT) 8-K Current Report: September 15, 2026

Item EX-99.1Item 7.01RCKT overview

Short answer

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on September 15, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). FDA alignment supports continued enrollment and dosing in RP-A501’s global pivotal Phase 2 Danon disease trial.

ROCKET PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • FDA alignment supports continued enrollment and dosing in RP-A501’s global pivotal Phase 2 Danon disease trial
  • Recalibrated dose and 12-patient pivotal population define the updated trial design
  • Established 12-month co-primary endpoints provide the efficacy and safety framework for potential regulatory evaluation

Item EX-99.1 · Exhibit EX-99.1

  • FDA alignment preserves RP-A501’s pivotal Phase 2 path and potential accelerated approval strategy in Danon disease
  • Pivotal population set at 12 male patients receiving 3.8 × 10¹³ GC/kg; first three patients count toward efficacy population
  • Nine additional patients remain; Rocket expects dosing completion by mid-2027
  • Initial safety review supported continued enrollment, with no observed thrombotic microangiopathy or capillary leak syndrome
  • Co-primary 12-month endpoints remain myocardial LAMP2 expression and 10% left-ventricular mass-index reduction

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ROCKET PHARMACEUTICALS, INC. 8-K filings

Get the next RCKT 8-K as it lands

Follow RCKT for push alerts, or ask the research agent what this filing means.